Paradigm Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Paradigm Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,200	Closed	-$55.2K	–	481
2017 Q2	$55.2K	Sell	1,200 -1,200	-50%	-$58.2K	0.01%	516
2017 Q1	$104K	Sell	2,400 -10,900	-82%	-$467K	0.02%	521
2016 Q4	$515K	Sell	13,300 -400	-3%	-$18.1K	0.1%	207
2016 Q3	$694K	Buy	+13,700	New	+$682K	0.12%	174
2016 Q2	–	Sell	-21,000	Closed	-$831K	–	812
2016 Q1	$831K	Hold	21,000	–	–	0.15%	124
2015 Q4	$1.19M	Sell	21,000 -45,200	-68%	-$2.3M	0.2%	104
2015 Q3	$2.63M	Sell	66,200 -14,500	-18%	-$701K	0.35%	91
2015 Q2	$3.85M	Hold	80,700	–	–	0.43%	79
2015 Q1	$3.2M	Buy	80,700 +13,400	+20%	+$479K	0.36%	89
2014 Q4	$1.5M	Sell	67,300 -8,100	-11%	-$153K	0.19%	156
2014 Q3	$1.18M	Buy	+75,400	New	+$1.13M	0.17%	171

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paradigm Asset Management's NBIX Position: Q3 2017 in Review

Paradigm Asset Management sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 1,200 shares — an estimated $55.2K sold.

Paradigm Asset Management first reported a position in NBIX in Q3 2014 and held it in 11 quarters. The position peaked at $3.85M in Q2 2015. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

Paradigm Asset Management reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
Paradigm Asset Management sold 1,200 Neurocrine Biosciences shares in Q3 2017, an estimated $55.2K.
Paradigm Asset Management first reported a position in Neurocrine Biosciences in Q3 2014 and held it in 11 quarters.
Paradigm Asset Management's Neurocrine Biosciences position peaked at $3.85M in Q2 2015.
223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.